Mali Barbi, Medical Oncologist at Northwell Health, shared a post on X:
“AACR26, NeoZanHER – the finding nobody is talking about Zanidatamab monotherapy in early HER2 IHC 3+, ERBB2-amplified breast cancer. No chemotherapy.
- 30% pCR
- Much less toxicity
- 56% HER2 downregulation in residual tumor after treatment
That last number is the story. Zanidatamab strips HER2 expression from surviving cells through receptor clustering and internalization. Residual tumor after this drug may look HER2-low or zero. Standard adjuvant T-DM1 in non-pCR patients assumes HER2 is still there. After zanidatamab – it may not be. Sequencing question nobody has answered yet.”
Other Articles Featuring Mali Barbi on OncoDaily.